- Home
- CYCN vs CDIO Comparison
CYCN vs CDIO Comparison
Compare CYCN & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- CDIO
- Stock Information
- Founded
- CYCN 2018
- CDIO 2017
- Country
- CYCN United States
- CDIO United States
- Employees
- CYCN N/A
- CDIO N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CYCN Health Care
- CDIO Health Care
- Exchange
- CYCN Nasdaq
- CDIO Nasdaq
- Market Cap
- CYCN 7.6M
- CDIO 6.8M
- IPO Year
- CYCN N/A
- CDIO N/A
- Fundamental
- Price
- CYCN $1.41
- CDIO $3.95
- Analyst Decision
- CYCN
- CDIO
- Analyst Count
- CYCN 0
- CDIO 0
- Target Price
- CYCN N/A
- CDIO N/A
- AVG Volume (30 Days)
- CYCN 1.0M
- CDIO 32.6K
- Earning Date
- CYCN 11-07-2025
- CDIO 11-14-2025
- Dividend Yield
- CYCN N/A
- CDIO N/A
- EPS Growth
- CYCN N/A
- CDIO N/A
- EPS
- CYCN N/A
- CDIO N/A
- Revenue
- CYCN $2,174,000.00
- CDIO $19,507.00
- Revenue This Year
- CYCN N/A
- CDIO $1,434.82
- Revenue Next Year
- CYCN N/A
- CDIO $4,661.91
- P/E Ratio
- CYCN N/A
- CDIO N/A
- Revenue Growth
- CYCN N/A
- CDIO N/A
- 52 Week Low
- CYCN $1.27
- CDIO $3.22
- 52 Week High
- CYCN $9.47
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- CYCN 34.60
- CDIO 43.29
- Support Level
- CYCN $1.60
- CDIO $3.70
- Resistance Level
- CYCN $2.23
- CDIO $3.99
- Average True Range (ATR)
- CYCN 0.16
- CDIO 0.30
- MACD
- CYCN -0.03
- CDIO -0.04
- Stochastic Oscillator
- CYCN 2.41
- CDIO 16.67
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.